Lead Plaintiff Deadline: March 20, 2023
Please Upload related files below
Fill in below.
Looking for more?
common stock on the open market, or pursuant to registration statements filed with the U.S. Securities and Exchange Commission, during the period October 6, 2020 through October 28, 2022
(i) Y-mAbs misrepresented the U.S. Food and Drug Administration’s (“FDA”) willingness to approve omburtamab, the Company’s lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA’s requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.
In order to be included in the lawsuit, you must have incurred a loss on shares of Y-mAbs, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of Y-mAbs, if applicable.
If you suffered a loss in Y-mAbs during the relevant time frame, or pursuant to Y-mAbs’s IPO if listed above, you have until March 20, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.